MediciNova. has filed a patent for a method of treating post-COVID conditions in patients by administering ibudilast or a pharmaceutical salt thereof. The method involves providing a therapeutically effective amount of the drug to the patient. GlobalData’s report on MediciNova gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights MediciNova Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on MediciNova, Peptide pharmacophores was a key innovation area identified from patents. MediciNova's grant share as of September 2023 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Method of treating post-covid condition using ibudilast

Source: United States Patent and Trademark Office (USPTO). Credit: MediciNova Inc

A recently filed patent (Publication Number: US20230285367A1) describes a method for treating post-COVID conditions in patients. The method involves administering ibudilast, or a pharmaceutical salt thereof, in a therapeutically effective amount to the patient.

The post-COVID conditions that can be treated using this method include anxiety, general pain or discomfort, fatigue, insomnia, cognitive impairment, depression, shortness of breath, post-traumatic stress disorder, joint pain, muscle pain, chest pain or tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss, and rash. Specifically, cognitive impairment can include memory lapse and impaired concentration.

The administration of ibudilast can be done through various routes, including oral, intravenous, subcutaneous or intramuscular injection, and inhalation. The duration of administration can range from 1 to 10 days or more, with a minimum of 2 months for effective treatment. Ibudilast can be administered once or twice daily, and the therapeutically effective amount can vary from 0.1 mg to 720 mg per day. The recommended range for effective treatment is 30 mg to 200 mg per day, or 60 mg to 600 mg daily. The therapeutically effective amount can be given as a single dose or divided into multiple doses.

In some cases, ibudilast can be the only active agent administered to the patient, while in others, it can be combined with other active agents. The additional active agents can include corticosteroids, COX-2 inhibitors, NSAIDs, SSRIs, SNRIs, tricyclic antidepressants, antihistamines, beta-blockers, cannabidiol, ATP, ifenprodil tartrate, neurotropin, gabapentin, pregabalin, mirtazapine, or a combination of two or more of these agents.

This patent filing provides a method for treating various post-COVID conditions using ibudilast, either alone or in combination with other active agents. The flexibility in administration routes, dosage, and duration allows for personalized treatment based on the specific condition and needs of the patient. Further research and clinical trials will be necessary to validate the effectiveness and safety of this method.

To know more about GlobalData’s detailed insights on MediciNova, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies